Table 1 Baseline patient characteristics in patients receiving G-B in cohort 1 of the GREEN study (intent-to-treat population)

From: Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study

Characteristic

All patients (N = 158)

Median age, years (range)

69.0 (42–83)

Male/female, n (%)

103/55 (65.2/34.8)

CIRS >6, n (%)

28 (17.7)

CrCl <70 ml/min, n (%)

73 (46.2)

CrCl <50 ml/min, n (%)

21 (13.3)

CIRS >6 and CrCl <70 ml/min, n (%)

13 (8.2)

Fitness, n (%)

 Fita

70 (44.3)

 Unfitb

88 (55.7)

Binet stage at screening, n (%)

 A

48 (30.4)

 B

57 (36.1)

 C

53 (33.5)

Absolute lymphocyte count, N = 155, n (%)

 ≥50 × 109/l

88 (56.8)

Tumor bulk, N = 139, n (%)

 ≥5 cm

95 (68.3)

Genomic aberrations, N = 146, n (%)c

 17p deletion

11 (7.5)

 11q deletion

26 (17.8)

 12q trisomy

26 (17.8)

 13q deletion

52 (35.6)

 Other abnormality

6 (4.1)

 Normal

25 (17.1)

IGHV, N= 136, n (%)

 Unmutated

92 (67.6)

 Mutated

44 (32.4)

ZAP70, N = 129, n (%)

 Positive

82 (63.6)

 Negative

47 (36.4)

CD38, N = 129, n (%)

 Positive

70 (54.3)

 Negative

59 (45.7)

  1. CIRS Cumulative Illness Rating Scale, CrCl creatinine clearance, G-B obinutuzumab plus bendamustine, IGHV immunoglobulin heavy variable chain
  2. a CIRS ≤6 and CrCl ≥70 ml/min
  3. b CIRS >6 and/or CrCl <70 ml/min
  4. c According to the hierarchical model of genomic aberrations [29]